Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to PET ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Neuroendocrine tumors-less well known, often misunderstood, and rapidly growing in incidence.JAMA Oncol. 2020; 6: 21-22
- Gastroenteropancreatic neuroendocrine tumors.CA Cancer J Clin. 2018; 68: 471-487
- Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?.Curr Oncol Rep. 2021; 23: 43
- Neuroendocrine tumor disease: an evolving landscape.Endocr Relat Cancer. 2012; 19: R163-R185
- Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions.J Nucl Med. 2016; 57: 1949-1956
- Neuroendocrine tumor diagnosis and management: (68)Ga-DOTATATE PET/CT.AJR Am J Roentgenol. 2018; 211: 267-277
- Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.Endocr Relat Cancer. 2005; 12: 1083-1092
- Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2020; 31: 844-860
- Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw. 2021; 19: 839-868
- Neuroendocrine tumours: what gastroenterologists need to know.Frontline Gastroenterol. 2022; 13: 50-56
- Immunohistochemical expression of somatostatin receptor subtypes in a panel of neuroendocrine neoplasias.J Histochem Cytochem. 2019; 67: 735-743
- The correlation between [(68)Ga]DOTATATE PET/CT and cell proliferation in patients with GEP-NENs.Mol Imaging Biol. 2019; 21: 984-990
- ACR practice parameter for the performance of gallium-68 DOTATATE PET/CT for neuroendocrine tumors.Clin Nucl Med. 2018; 43: 899-908
- Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors.J Nucl Med. 2018; 59: 66-74
- Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?.Eur J Nucl Med Mol Imaging. 2007; 34: 982-993
- Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.Eur J Nucl Med. 2000; 27: 273-282
- Head-to-Head comparison of (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors.J Nucl Med. 2017; 58: 451-457
- Influence of lanreotide on uptake of (68)Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation.Eur J Nucl Med Mol Imaging. 2019; 46: 696-703
- Physiological biodistribution of (68)Ga-DOTA-TATE in normal subjects.Mol Imaging Radionucl Ther. 2021; 30: 39-46
- Somatostatin receptor imaging and theranostics: current practice and future prospects.J Nucl Med. 2021; 62: 1323-1329
- Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation.Radiographics. 2015; 35: 500-516
- New directions in imaging neuroendocrine neoplasms.Curr Oncol Rep. 2021; 23: 143
- Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis.Virchows Arch. 2002; 440: 461-475
- Localization of insulinoma using 68Ga-DOTATATE PET/CT scan.J Clin Endocrinol Metab. 2017; 102: 195-199
- The added value of (68)Ga-DOTA-TATE-PET to contrast-enhanced CT for primary site detection in CUP of neuroendocrine origin.Eur Radiol. 2017; 27: 1676-1684
- Somatostatin receptor PET/CT imaging for the detection and staging of pancreatic NET: a systematic review and meta-analysis.Diagnostics (Basel). 2020; 10: 598
- Results of (68)Gallium-DOTATATE PET/CT scanning in patients with multiple endocrine neoplasia type 1.J Am Coll Surg. 2015; 221: 509-517
- Effect of metastatic site on survival in patients with neuroendocrine neoplasms (NENs). An analysis of SEER data from 2010 to 2014.BMC Endocr Disord. 2020; 20: 44
- TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.Virchows Arch. 2007; 451: 757-762
- TNM staging of pancreatic neuroendocrine tumors: an observational analysis and comparison by both AJCC and ENETS systems from 1 single institution.Medicine (Baltimore). 2015; 94: e660
- Clinical value of (6)(8)Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET).Eur J Radiol. 2015; 84: 1866-1872
- Impact of (68)Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum.Ann Surg Oncol. 2015; 22: 164-171
- The Impact of 68Ga-DOTATATE PET/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom.J Nucl Med. 2016; 57: 34-40
- 68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor.Int J Endocr Oncol. 2018; 5: IJE04
- Recurrence patterns after surgical resection of gastroenteropancreatic neuroendocrine tumors: analysis from the national comprehensive cancer network oncology outcomes database.Pancreas. 2021; 50: 506-512
- Recurrence in resected gastroenteropancreatic neuroendocrine tumors.JAMA Oncol. 2018; 4: 583-585
- Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT.Radiology. 2014; 270: 517-525
- Somatostatin receptor SSTR-2a expression is a stronger predictor for survival than Ki-67 in pancreatic neuroendocrine tumors.Medicine (Baltimore). 2015; 94: e1281
- The utility of (68)Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors.Future Oncol. 2018; 14: 111-122
- Role of somatostatin receptor in pancreatic neuroendocrine tumor development, diagnosis, and therapy.Front Endocrinol. 2021; 12: 679000
- 68) Ga-DOTATATE Positron emission tomography-computed tomography quantification predicts response to somatostatin analog therapy in gastroenteropancreatic neuroendocrine tumors.Oncologist. 2021; 26: 21-29
- NANETS/SNMMI consensus statement on patient selection and appropriate use of (177)Lu-DOTATATE peptide receptor radionuclide therapy.J Nucl Med. 2020; 61: 222-227
- 68)Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours.Radiother Oncol. 2019; 141: 108-115
- Prognostic significance of somatostatin receptor heterogeneity in progressive neuroendocrine tumor treated with Lu-177 DOTATOC or Lu-177 DOTATATE.Eur J Nucl Med Mol Imaging. 2020; 47: 881-894
- Predictive and prognostic role of pre-therapy and interim 68Ga-DOTATOC PET/CT parameters in metastatic advanced neuroendocrine tumor patients treated with PRRT.Cancers (Basel). 2022; 14: 592
Article info
Publication history
Published online: December 28, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
